Trials / Recruiting
RecruitingNCT04006808
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 184 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 1 Year – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PED-HZ/su | GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups. |
Timeline
- Start date
- 2019-10-25
- Primary completion
- 2026-05-01
- Completion
- 2027-03-31
- First posted
- 2019-07-05
- Last updated
- 2026-02-27
Locations
31 sites across 6 countries: Belgium, France, Italy, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04006808. Inclusion in this directory is not an endorsement.